Bio-Rad Laboratories (BIO) Q1 2026 Earnings
Bio-Rad Laboratories reported Q1 2026 revenue of $592.1M (+1.1% YoY), beat analyst consensus of $589.9M by $2.2M. Diluted EPS came in at $1.89 (-25.6% YoY), missed the $1.99 consensus by $0.10.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Bio-Rad Laboratories's Q1 2026 earnings report.
Bio-Rad Laboratories (BIO) reported Q1 2026 earnings on April 30, 2026 after market close.
Bio-Rad Laboratories reported revenue of $592.1M and diluted EPS of $1.89 for Q1 2026.
Revenue beat the consensus estimate of $589.9M by $2.2M. EPS missed the consensus estimate of $1.99 by $0.10.
Compared to the same quarter a year prior, revenue grew 1.1% from $585.4M a year earlier and diluted EPS declined 25.6% from $2.54.
You can read the 8-K earnings release (0000012208-26-000034) and the 10-Q periodic report (0000012208-26-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.